Trump Administration Eyes Ibogaine Research For PTSD Treatment, Stock Jumps - Psyence Biomedical (NASDAQ:
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested - Enveric Biosciences (NASDAQ:ENVB)
Enverics führender Medikamentenkandidat aktiviert Schlüssel-Signalwege zur Linderung von Depressionen